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In this study we evaluated the time dependence in cadmium-nicotine interaction and its effect on motor function, anxiety linked
behavioural changes, serum electrolytes, and weight after acute and chronic treatment in adult male mice. Animals were separated
randomly into four groups of n = 6 animals each. Treatment was done with nicotine, cadmium, or nicotine-cadmium for 21 days.
A fourth group received normal saline for the same duration (control). Average weight was determined at 7-day interval for the
acute (D1-D7) and chronic (D7-D21) treatment phases. Similarly, the behavioural tests for exploratory motor function (open field
test) and anxiety were evaluated. Serum electrolytes were measured after the chronic phase. Nicotine, cadmium, and nicotine-
cadmium treatments caused no significant change in body weight after the acute phase while cadmium-nicotine and cadmium
caused a decline in weight after the chronic phase. This suggests the role of cadmium in the weight loss observed in tobacco smoke
users. Both nicotine and cadmium raised serum Ca2+ concentration and had no significant effect on K+ ion when compared with
the control. In addition, nicotine-cadmium treatment increased bioaccumulation of Cd2+ in the serum which corresponded to a
decrease in body weight, motor function, and an increase in anxiety.
1. Introduction
Wide arrays of behavioural and physiological responses have
reportedly been observed following nicotine use either in
tobacco smoke or as a pure drug [1]. In human abusers
and rodent models, weight loss, anxiety, depression, and
motor dysfunctions are among the most frequently reported
behavioural changes [2–4]. Long and short term use of
nicotine in tobacco smoke alter synaptic function, neuro-
transmitter level, and the anatomical structure of the brain
to varying extents. Similarly, the addictive effect of nicotine
in tobacco smoke is known to potently alter the expression
of cholinergic receptors, serum level of ions, and neuro-
transmission (central and peripheral) [5]. Primarily, nicotine,
being a structural analogue of acetylcholine, potentiates the
receptors and facilitates the increase in intracellular Ca2+
concentration, vesicle formation, and neurotransmission at
synapses and neuromuscular junctions. However, prolonged
excitation of cholinergic synapses by nicotine leads to excito-
toxicity and synaptic dysfunction, observed in prolonged use
and abuse of nicotine [6–11].
Although nicotine gets into the body through various
means—such as chewing of tobacco leaves and absorption
of nicotine through the skin [12, 13]—the most predominant
route of nicotine use is through tobacco smoke in cigarettes
and pipes (respiratory) [14, 15]. Interestingly, several studies
have reported the presence of cadmium, carbon monoxide,
lead, cooper, silicon, and alkaloids in the tobacco smoke
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[14, 16]. Despite the striking evidence of the bioaccumulation
of cadmium in tobacco smoke, coupled with its ability to
inhibit cellular respiration in neurons, the metabolic and
behavioural changes associated tobacco smoke has often been
restricted to nicotine and its associated functions. Although
cadmium is a trace element in the blood, previous studies
have shown that the level of cadmium in the serum of
smokers is usually 30–50% higher than that of nonsmokers
[17–19]. Furthermore, overproduction of carbon dioxide,
due to cadmium-mediated mitochondria stress, has been
reported to induce synaptic inhibition at cholinergic endings
in the nervous system [18, 19]. Consequently, the reactive
oxygen species (ROS), generated from cadmium blockade of
cytochrome a3 and cytochrome C, participates in the elevation
of cellular calcium concentration, peroxidation of neuronal
membrane, and degeneration of neurons [20–23].
The bioavailability and effect of nicotine and (or) cad-
mium in the blood are known to be dependent on the
duration of exposure to these substances either solely or
combined in tobacco smoke [24–26]. Similarly, differences
in the magnitude of addiction or degenerative changes seen
in the brain, after a time-dependent tobacco smoke abuse,
vary with the sex, age, and the developmental stage of the
individual [27, 28]. Females, generally, are more sensitive to
nicotine addiction than males, which also show less toxicity
compared with the females [27]. Consequently, the long
term effect of tobacco abuse in males has been found to
be linked with irrational behaviour, violence, anxiety, mood
disorders, movement disorders, and weight loss [27, 29–31].
Furthermore, movement and anxiety are affected due the
effect of nicotine on reward brain regions and brain stress
systems involving dopaminergic regulation, epinephrine,
neuropeptide Y, and neuromuscular nicotinic stimulation
[31–34].
Although the effect of nicotine (tobacco) on metabolism,
anxiety, motor function, and brain reward has been studied
extensively, the specific role of cadmium-nicotine treatment
on these parameters (metabolism, anxiety and motor func-
tion) are yet to be elucidated, comparatively, the effect of
cadmium, nicotine, and a combination of nicotine-cadmium
treatment in male adult mice. We investigated pharmaco-
logically the effect of nicotine and (or) cadmium treatment
on the body weight, motor function, and anxiety linked
behavioural changes during acute and chronic treatment
phases. Furthermore, we sought to identify the synergistic
effect of nicotine and cadmium on metabolism, anxiety, and
exploratory motor dysfunction seen in tobacco abuse.
2. Materials and Methods
Cadmiumchloride and nicotinewere a generous gift formDr.
Maria Deluca of the University of Cagliari, while the normal
saline used for the preparation was procured from Kanada
Pharmaceuticals, Nigeria. The test chemicals were prepared
weekly in normal saline and applied within the same period.
2.1. Treatment. Male adult albino Swiss mice (𝑁 = 24),
each weighing between 19 and 22 gms, were used for this
study. The animals were obtained from the animal holding
facility of Obafemi AwolowoUniversity, Nigeria, and allowed
to acclimatize for 7 days before the commencement of
treatment. Subsequently, four (4) separate groups of 𝑛 = 6
animals each were created at random and maintained in a
standard laboratory environment with controlled humidity,
pressure, and temperature. Treatment protocols were in
accordance with the ethical requirements of the Animal
Use and Care Committee of the Afe Babalola University,
Nigeria. Animals (all groups) were treated once daily for a
duration of 21 days (D1–D21); days 1–7 represent the acute
treatment while days 7–21 are the chronic treatment phase.
A group of 𝑛 = 6 mice received 1.4mg/Kg BW of cadmium
chloride prepared in normal saline (intramuscular). Another
group received 0.4mg/Kg BW of nicotine (subcutaneous)
[35, 36] while a combined treatment group received nicotine
(subcutaneous; 0.4mg/Kg) and cadmium (intramuscular
1.4mg/Kg) [37, 38]. The control was treated with normal
saline (subcutaneous) for the duration of the experiment
(Table S1 in the Supplementary Material available online at
http://dx.doi.org/10.1155/2014/359436).
2.2. Weight Measurement. Average weight per group (gms)
wasmeasured at days 1, 7, 14, and 21 using a sensitive weighing
balance (Jenway) and plotted (ANOVA) to compare weight
changes for the treatment groups versus the control.
2.3. Open Field Test. This was done to determine exploratory
motor function relative to anxiety linked behavior in a single
test [39]. The animals were trained in the open field area
(OFA) continually for 4 days before the actual test to facilitate
acclimatization to the test equipment and environment. In
addition, the animals were assisted to move or navigate the
open field area when necessary during the training phase.
OFA was made of white wood with dimensions, 100 cm wide,
100 cm long, and 45 cm high, and was marked with dark lines
dividing the floor into 16 uniform squares and a center square.
A high definition video recording system (SONY) was placed
in position to capture all corners and sides of theOFA in order
to record animal movement and behavior. For the actual test,
animals were placed in the OFA and allowed to explore for
5 minutes following which analysis was done for motor and
anxiety related functions.
2.4. Evaluation of Motor Function. This was done by estimat-
ing the average number of lines crossed per animal/per group
for the duration of the test (5 minutes) and was expressed
as the frequency of lines crossed after the acute and chronic
treatment phases.
2.5. Anxiety Linked Behaviors. This was evaluated in relation
to the observed motor functions in the OFA. Center square
duration, frequency of grooming, and rearing were estimated
and analyzed after the acute and chronic treatment phases to
determine the level of anxiety linked with exploratory motor
behavior.
2.6. Blood Electrolyte Concentration. At the end of the
chronic phase, the animals were euthanized humanely to
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obtain blood through cardiac puncture. Subsequent process-
ing involved the use of anticoagulant (heparin), followed
by centrifugation at 4∘C to obtain the cold serum. The
concentrations of Ca2+, K+, Na+, and Cd2+ were determined
in a mass atomic spectrometry as previously described [40].
Serum was diluted and spiked with enriched radioisotopes
following which the primary standards were measured in
analogue mode for 𝑛 = 6 samples per group.
2.7. Statistical Analysis. Data was plotted in ANOVA for all
behavioral tests, weight, and electrolyte concentrations from
mass spectrometry. Statistical significance was determined
usingGraphPad Prism (Version 6) (∗𝑃 < 0.05) and expressed
as mean ± SEM (standard error of mean).
3. Results
3.1. Change in Average Weight. The comparative weight
analysis for nicotine, cadmium, or a combined treatments
showed that nicotine treatment caused a significant increase
in body weight (𝑃 < 0.05) while cadmium (𝑃 < 0.001)
treatment induced a decline in body weight when compared
with the control. Similarly, a combined nicotine-cadmium
treatment decreased the body weight of the animals versus
the control (𝑃 < 0.01) during the acute phase (D1–
D7). However, following chronic administration (D7–D21)
further decline in weight was observed in the cadmium
and cadmium-nicotine treatment groups when compared
with the control (𝑃 < 0.01). Nicotine treatment caused
a significant increase in average body weight during the
chronic treatment phase recording a significance of 𝑃 < 0.05
versus the control (Figure 1). These findings suggest that
the weight loss associated with tobacco smoke is a result of
cadmium or tobacco cadmium synergy rather than nicotine
only; nicotine treatment increased the body weight both in
the chronic and acute phases.
3.2. Metal Ion Analysis in Serum
3.2.1. Sodium (Na+). Spectrum analysis showed that cad-
mium treatment increased serum Na+ ion level significantly
above the values observed for the control. No significant
change was observed in the nicotine and nicotine-cadmium
treatment group when compared with the control (Fig-
ure 2(a)).
3.2.2. Calcium (Ca2+). The concentration of calcium in the
serum of the treatment groups showed no significant change
among the treatment groups for the duration of treatment (21
days). The control group recorded the lowest calcium con-
centration in the blood when compared with the treatments.
This suggests the role of calcium in the activity of nicotine
and cadmium and the significance of raised calcium levels in
both cadmium and nicotine toxicity (Figure 2(b)).
3.2.3. Potassium (K+). Although alterations in potassium
levels were statistically insignificant, empirically, cadmium
treatment and nicotine-cadmium treatment groups showed
an increase in K+ ion level when compared with the nicotine
Bo
dy
 w
ei
gh
t (
gm
s)
Treatment duration (days)
Cadmium
Cad-Nic
Control
Nicotine
Acute Chronic
28
26
24
22
20
D1 D7 D14 D21
Figure 1: Comparative body weight analysis for Cd, Nc, Cd-Nc,
and control group after the acute and chronic treatment phases.
As a result of acute nicotine treatment, an increase in body weight
was observed in the acute (D1–D7) and chronic treatment phases
(D7–D21). However, comparing the nicotine treated animals and
the control, only a slight change in body weight was seen (𝑃 <
0.05). Administration of cadmium caused an increase in body
weight after the acute phase; subsequently, a decline in body weight
was seen after chronic treatment with cadmium (𝑃 < 0.001)
versus the control. Similarly, combined treatment with nicotine
and cadmium induced an increase in body weight after the acute
treatment phase, followed by a decline after chronic treatment. In
addition, the decrease in body weight observed in the nicotine-
cadmium treatment group was lower than the average body weight
for nicotine treatment but higher than the weight recorded in
cadmium treatment group.The averageweight/ groupwas expressed
as mean ± standard error of mean (SEM) (∗𝑃 < 0.001, Cd2+ versus
Nic; ∧P > 0.05, Cd2+ versus Cd2+ +Nic; ×𝑃 > 0.05, Nic versus Cd2+ +
Nic; #𝑃 < 0.001, Cd2+ versus control; §𝑃 > 0.05, Nic versus control;
and 𝛼𝑃 > 0.05, Cd2+ + Nic versus control).
treatment and the control. The potassium ion concentration
change also correlated with Ca2+ ion level change in the
treatment and control groups (Figure 2(c)).
3.2.4. Cadmium (Cd2+). The cadmium concentration in
the cadmium and nicotine treatments reduced significantly
when compared with the control and the nicotine-cadmium
treatment groups. In the cadmium-nicotine treatment, blood
Cd2+ level increased significantly when compared with the
control, cadmium, and nicotine treatment groups (Fig-
ure 2(d)). This suggests the role of nicotine in increased
bioaccumulation of Cd2+ in the blood of tobacco smokes.
Also, we observed that cadmium treatment was associated
with reduced serum Cd2+; although the mechanism involved
is unclear, it is suspected to have resulted from the rapid
clearance from the blood in urine and other physiological
means (positive feedback).
3.3. Motor Function. Theopen field test (OFT) was employed
to evaluate exploratory motor functions after the acute
phase (D1–D7) and the chronic phase (D7–D21). Subsequent
analysis involved determination of the frequency of lines
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Figure 2: Concentration (mg/dL) of Na+, K+, and Ca2+ and cadmium in the blood. (a) Bar chart showing the level for Na+ in blood (mg/mL).
An increase in Na+ was associated with cadmium treatment when compared with the control (𝑃 < 0.05). (b) An empirical increase in Ca2+
concentration was observed in the blood of the treatment groups when compared with the control (𝑃 < 0.05). (c) Concentration of K+ in
blood; no significant change was seen in the K+ ion concentration after nicotine and (or) cadmium treatment. (d) Bar chart demonstrating
the blood level of cadmium in the treatment groups and control. An increase in Cd2+ was observed in the nicotine-cadmium treatment versus
the control (𝑃 < 0.05).
crossed in the open field area (OFA) for the nicotine,
cadmium, nicotine-cadmium, and control groups. After the
acute treatment phase, nicotine treatment caused an increase
in exploratory motor activity when compared with the cad-
mium and nicotine-cadmium treatment groups (𝑃 < 0.05).
Similarly, the cadmium and nicotine-cadmium treatment
recorded a significant decline in motor function versus the
control (𝑃 < 0.01). After chronic treatment (D21), the
nicotine group recorded an increase in motor function when
compared with the control (𝑃 < 0.05). Also, the nicotine-
cadmium treatment showed an increase in motor function
versus the control (𝑃 < 0.05) while cadmium treatment
recorded a significant decline in exploratory motor function
versus the control (𝑃 < 0.001) (Figure 3).
3.4. Centre Square Duration (CSD). No significant change
was observed in the CSD after the acute treatment phase
(Figure 4(a)) when the treatment groups were compared
with the control. However, after the chronic treatment
phase, nicotine, cadmium, and nicotine-cadmium treatment
showed a significant decrease in CSD (𝑃 < 0.001) when
compared with the control. This was observed as an increase
in time spent exploring the corners andwalls of the open field
area (↑anxiety) (Figure 4(a)).
3.5. Frequency of Rearing. No significant change was seen
after the chronic phase when the treatment groups were
comparedwith the control. Similarly, the cadmium treatment
group showed a decrease in the frequency of rearing versus
the control (𝑃 < 0.001). This was similar to our observations
in frequency of lines crossed (Figure 3) and the CSD (Fig-
ure 4(a)). Generally, the cadmium treatment group showed a
decline in motor function and an increase in anxiety related
behaviour when compared with the nicotine or nicotine-
cadmium treatment (Figure 4(b)).
3.6. Frequency of Grooming. No significant change was
observed in the treatment groups after the chronic and acute
phase versus the control (Figure 4(c)).
3.7. Analysis of Anxiety in OFT. From these findings, we
deduced that a time-dependent relationship exists between
the use of nicotine and (or) cadmium and the observed
increase in anxiety or decreased motor function. The
Journal of Neurodegenerative Diseases 5
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Figure 3: Motor function analysis in open field test (OFT) for Cd2+
and nicotine toxicity. Bar chart (acute phase) representing the fre-
quency of lines crossed in OFT for the treatment groups and control
after the acute (D1–D7) and chronic treatment phases (D7–D21).
No significant change in motor function was observed between the
treatment groups and control after the acute phase. However, after
the chronic phase, the cadmium (𝑃 < 0.01) treated group showed
a decline in motor function while the nicotine treatment showed
an increase in exploratory motor function when compared with
the control (𝑃 < 0.05). Similarly, the nicotine-cadmium treatment
recorded a significant increase in motor function when compared
with the cadmium treatment group (𝑃 < 0.05) and control.
most significant decline in exploratory motor function and
increase in anxiety were observed after chronic treatment of
cadmiumwhile no significancewas recorded after acute treat-
ment. In addition, nicotine increased motor function and
anxiety after the acute and chronic phases when compared
with the control. A combination of nicotine and cadmium
reduced the exploratory motor activity and increased anxiety
in the animals after the chronic phase, thus suggesting the
complimentary role of cadmium in observed anxiety related
behavioural changes seen in prolonged tobacco use (Figures
4(a)–4(c)).
4. Discussion
Taken together, the outcomes of this study prove that
cadmium is involved in the weight, anxiety, and motor
changes observed in tobacco (nicotine) use. We observed
that nicotine treatment increased the body weight after
the acute and chronic treatment phases while cadmium
caused a decrease in weight versus the control. Interestingly,
nicotine-cadmium treatment, similar to tobacco use, caused
a decline in body weight after the chronic treatment phase.
Subsequent analysis reveals that an increase in exploratory
motor activity was associated with nicotine use after the
acute and chronic treatment phases; however, an increase in
anxiety was also observed in this group. Consequently, cad-
mium and nicotine-cadmium treatment induced a decline
in exploratory motor activity and increased anxiety after the
chronic phase, further suggesting the complimentary effect of
cadmium on nicotine induced anxiety and decreased motor
coordination observed in chronic tobacco smoke exposure.
Furthermore, the effect of cadmium and nicotine was
also examined on electrolyte balance and bioaccumulation
of cadmium in the serum after the chronic phase (D21).
We observed that chronic cadmium treatment increased
serum Ca2+ and Na+ ion concentration when compared
with the control (Figures 2(a) and 2(b)). Similarly, nicotine
increased serum Ca2+ ion level, while no changes in K+ and
Cd2+ ion concentration were observed in nicotine and cad-
mium treatment groups (Figures 2(c) and 2(d)). Combined
nicotine-cadmium treatment did not cause any significant
change in serum Ca2+, Na+, and K+ ion concentrations when
compared with the control (Figures 2(a)–2(c)). Interestingly,
the nicotine-cadmium treatment increased the serum level
of Cd2+ ion significantly versus the control, nicotine, and
cadmium treatment groups (Figure 2(d)); this suggests the
role of nicotine in bioaccumulation of cadmium observed in
chronic exposure to tobacco smoke. The observed effects of
nicotine, cadmium, andnicotine-cadmiumcombination sug-
gest a rapid change in metabolism which is dependent on the
dose and duration of exposure [41, 42]. Furthermore, nicotine
and cadmium as separate entities have been implicated in
neurotoxicity and cell death by altering energy metabolism,
signal transduction, reward, and induction of brain stress
[43–46]. Previous studies have shown that the anxiety and
exploratory motor changes associated with acute and chronic
tobacco use involved alteration in neurotransmitters such as
GABA [47, 48], dopamine [49, 50], and norepinephrine in
brain [51]. Similarly, the nicotine in tobacco smoke affects the
level of acetylcholine and epinephrine in the neuromuscular
junction, arteries, glands, and other viscera [51, 52].
Dopaminergic D
1
and D
2
stimulation in the hip-
pocampus has been implicated in nicotine-mediated anxiety
and reward system [46–48, 53]. Nicotinic modulation of
dopaminergic system is believed to be involved in increased
motor function, brain reward, addiction, anxiety, and late
onset Parkinson’s disease observed in smokers [54, 55].
However, nicotinic stimulation of acetylcholine receptors
induces the release of acetylcholine and norepinephrine in
the central and peripheral nervous system and has been
found to involve transient calcium release and release of
high frequency pulses associated with anxiety and motor
dysfunctions [56]. Interestingly, cadmium and the associated
carbon dioxide produced in oxidative stress have been linked
with the inhibition of synaptic activity at cholinergic endings
[57, 58]. Although, its actual role in the modulation of
neurotransmitter and reward system is elusive, our find-
ings suggest nicotine increases the serum concentration of
cadmium when both molecules are coadministered. As a
result, both nicotinic stimulation of cholinergic receptors and
cadmium induced oxidative stress are capable of inducing
elevated calcium and sodium ions concentration in the serum
(Figure 2), an effect that is linked to the observed anxiety and
altered motor function in these groups.
Nicotine-mediated cholinergic stimulation also involves
the activation of neuropeptide Y and cAMP, which repre-
sents calciumdependentmechanisms involved in cholinergic
hippocampal-mediated anxiety, epinephrine-mediated anx-
iety, and cholinergic neuromuscular stimulation [59–62].
6 Journal of Neurodegenerative Diseases
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Figure 4: (a) Anxiety related behavioral analysis (I) in open field test (OFT) for Cd2+ and nicotine toxicity. Bar chart representing the center
square duration (CSD) in OFT for the treated groups and control after the acute (D1–D7) and chronic (D7–D21) treatment phases. The
duration spent in the center square of the open field area was estimated to determine the mean duration for each group at the end of the
acute and chronic phases. After the acute treatment phase, no significant change in anxiety linked behavior was seen in the nicotine and (or)
cadmium treatment groups. After chronic treatment, cadmium and nicotine treatment increased anxiety linked behavior in the animals, as
shown by a significant decrease in CSD (D7–D21). Similarly, a combined nicotine-cadmium treatment also caused an increase in anxiety
linked behavior (reduced CSD) when compared with the control (∧P < 0.001). (b) Anxiety related behavioral analysis (II) in open field test
(OFT) for the treatment and control groups.Themean frequency of rearing was determined for the nicotine and (or) treatment groups versus
the control after the acute (D1–D7) and chronic (D7–D21) treatment phases. No significant change in the frequency of rearing for the treatment
groups after the acute treatment phase. After the chronic phase, subsequent tests show a significant reduction in rearing time (↑anxiety) for the
cadmium treatment group when compared with the control, nicotine, and nicotine-cadmium treatment groups (∗∗∗𝑃 < 0.001). (c) Anxiety
related behavioral analysis (III) in open field test (OFT) for Cd2+ and (or) nicotine toxicity. Bar chart representing the frequency of grooming
in OFT for the treatment groups and control after the acute (D1–D7) and chronic (D7–D21) treatment phases. No significant change in the
frequency of grooming was observed after the acute treatment phase. Similarly, no significant change was seen in the frequency of grooming
after the chronic treatment phase for all treatment groups versus the control.
Similarly, cadmium inhibits cytochrome C and a3 in themito-
chondria leading to ROS-dependent calcium release, anxiety,
and synaptic excitotoxicity [63, 64]. Other studies have
shown that cadmium affects the level of monoamine in the
hypothalamus and hippocampus without a corresponding
change in norepinephrine [63]. Interestingly, an increase
in anxiety index was observed in the cadmium treated
animals, similar to our findings. However, the mechanism
of nicotine-induced bioaccumulation of cadmium and its
relationship with the anxiety linked behavioural changes
remains elusive. Based on the outcome of this study and
previous studies, we hypothesise that cadmium-mediated
synaptic inhibition, monoaminergic alterations, and induced
calcium-shift are important in anxiety linked behaviour and
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decline in motor functions. As a result it complements the
neural and behavioural changes attributed to nicotine in long
term tobacco use.
5. Conclusion
Based on the outcome of this study, we infer that the
motor and anxiety related behavioural changes observed
in prolonged tobacco use in adult male mice are a result
of the synergistic effect of nicotine-cadmium on synaptic
plasticity, neurotransmitter function, and brain reward sys-
tem. Also, nicotine and cadmium increased serum Ca2+ ions
and caused no significant change in K+ ion concentration.
However, combined nicotine-cadmium showed that nicotine
facilitates bioaccumulation of cadmium in serum, resulting
in a decrease in motor function and increased anxiety
when compared with the nicotine and cadmium treatment
groups. In addition, nicotine induced increase in weight
during the acute and chronic phases while cadmium and
cadmium-nicotine treatment caused a decrease in weight
after the chronic phase. Ultimately, we conclude that nicotine
and cadmium interaction in tobacco use is time-dependent
and affects metabolism, electrolytes, and neurotransmitter
functions that translate into the observed increased anxiety,
decreased weight and altered motor function after chronic
treatment.
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